USANA Health Sciences (NYSE:USNA) Cut to Strong Sell at Zacks Research

Zacks Research downgraded shares of USANA Health Sciences (NYSE:USNA) from a hold rating to a strong sell rating in a research note issued to investors on Wednesday morning,Zacks reports.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Wall Street Zen lowered shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Two equities research analysts have rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has an average rating of “Sell”.

USANA Health Sciences Trading Down 1.7%

NYSE:USNA opened at $13.62 on Wednesday. The company has a market capitalization of $251.75 million, a P/E ratio of -11.85, a price-to-earnings-growth ratio of 1.61 and a beta of 0.66. The firm has a 50-day moving average price of $14.60 and a two-hundred day moving average price of $17.95. USANA Health Sciences has a twelve month low of $12.57 and a twelve month high of $23.59.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.22). USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. The business had revenue of $205.89 million during the quarter, compared to analysts’ expectations of $217.42 million. On average, equities research analysts predict that USANA Health Sciences will post 0.55 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of USANA Health Sciences during the second quarter worth about $33,182,000. Pzena Investment Management LLC acquired a new position in shares of USANA Health Sciences in the second quarter valued at $25,739,000. Nantahala Capital Management LLC bought a new position in shares of USANA Health Sciences in the second quarter worth about $17,295,080. Algert Global LLC increased its stake in USANA Health Sciences by 91.8% in the second quarter. Algert Global LLC now owns 131,758 shares of the company’s stock valued at $2,813,000 after purchasing an additional 63,074 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in USANA Health Sciences in the 1st quarter valued at $1,265,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences News Roundup

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti raised its Q4 2026 EPS estimate slightly, to $0.12 from $0.11, though this was outweighed by reductions to other forecasts.
• Neutral Sentiment: USANA updated its fiscal 2026 earnings guidance, and its Q3 2026 earnings-call transcript was published. The supplied headlines do not provide details of the guidance update. USANA fiscal 2026 guidance update
• Negative Sentiment: Zacks Research downgraded USANA from “hold” to “strong sell,” a notably bearish change in analyst sentiment. Zacks downgrade report
• Negative Sentiment: Sidoti cut its FY2026 EPS estimate to $0.55 from $0.76, and lowered its FY2027 forecast to $1.59 from $1.77. It also reduced estimates for Q1–Q3 2027, signaling weaker expected earnings.
• Negative Sentiment: The supplied earnings background also shows USANA’s latest quarter missed analyst expectations for both EPS and revenue, adding to concerns about near-term performance.

About USANA Health Sciences

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.